Mustang Bio Inc (NAS:MBIO)
$ 0.4865 -0.0725 (-12.97%) Market Cap: 15.21 Mil Enterprise Value: 16.27 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

Mustang Bio Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 20, 2021 / 04:25PM GMT
Release Date Price: $39.15 (-9.38%)
Jacqueline Lu
Oppenheimer & Co. Inc. - Analyst

Hi, everyone. Thank you so much for joining us for Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit. My name is Jacqueline Lu, and I am part of Oppenheimer's biotechnology equity research team.

I'm happy to introduce our next presenting company, Mustang Bio, and its CEO, Manuel Litchman. Mustang is developing a pipeline of novel CAR T therapies and lentiviral gene therapies for cancer and rare diseases. We will be sure to leave a few minutes at the end for Q&A. (Conference Instructions) With that, I will turn the microphone over to Manny so he can talk us through Mustang's story.

Manuel Litchman
Mustang Bio, Inc. - President & CEO

Thank you, Jacqueline. Mustang Bio is building a fully integrated gene cell therapy company. We are located on the campus of the University of Massachusetts Medical School in Worcester, Massachusetts. You can see our building on the upper-right corner -- on the upper-left corner of the slide. We have 27,000 square feet that is fully built out to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot